1. Home
  2. PRA vs IOVA Comparison

PRA vs IOVA Comparison

Compare PRA & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProAssurance Corporation

PRA

ProAssurance Corporation

HOLD

Current Price

$24.75

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.37

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRA
IOVA
Founded
1976
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2000
2008

Fundamental Metrics

Financial Performance
Metric
PRA
IOVA
Price
$24.75
$3.37
Analyst Decision
Hold
Buy
Analyst Count
1
10
Target Price
$25.00
$9.00
AVG Volume (30 Days)
890.1K
13.9M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.84
EPS
0.99
N/A
Revenue
$1,098,028,000.00
N/A
Revenue This Year
N/A
$47.74
Revenue Next Year
N/A
$40.31
P/E Ratio
$24.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.79
$1.64
52 Week High
$24.85
$5.63

Technical Indicators

Market Signals
Indicator
PRA
IOVA
Relative Strength Index (RSI) 56.51 43.04
Support Level $23.88 $2.03
Resistance Level $24.79 $4.33
Average True Range (ATR) 0.11 0.21
MACD 0.02 -0.04
Stochastic Oscillator 82.84 12.14

Price Performance

Historical Comparison
PRA
IOVA

About PRA ProAssurance Corporation

ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in four segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: